Influenza vaccines for the future.

New technologies can revolutionize influenza vaccine design, production, and delivery. In the near future, advances should reduce vaccine production time, provide enhanced protection, and end mismatches between vaccine strains and circulating viruses.

[1]  R. Compans,et al.  Influenza virus-like particles as pandemic vaccines. , 2009, Current topics in microbiology and immunology.

[2]  J. Kaiser.  A One-Size-Fits-All Flu Vaccine? , 2006, Science.

[3]  J. Oxford,et al.  DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. , 2009, Vaccine.

[4]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[5]  J. Taubenberger,et al.  Influenza : the Mother of All Pandemics , 2022 .

[6]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[7]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[8]  Larry R. Smith,et al.  Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. , 2010, Vaccine.

[9]  Y. Yoshioka,et al.  The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. , 2009, Biomaterials.

[10]  B. Murphy,et al.  Newcastle Disease Virus-Vectored Vaccines Expressing the Hemagglutinin or Neuraminidase Protein of H5N1 Highly Pathogenic Avian Influenza Virus Protect against Virus Challenge in Monkeys , 2009, Journal of Virology.

[11]  G. Poggensee,et al.  Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[13]  S. Cryz,et al.  A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. , 1996, Vaccine.

[14]  A. García-Sastre,et al.  Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Katinger,et al.  Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes , 2004, Journal of Virology.

[16]  Penny M Heaton.  Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults , 2009 .

[17]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[18]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[19]  R. Ness.  Public Health Research Priorities For The Future , 2011, Public health reviews.

[20]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  A. Osterhaus,et al.  MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization , 2009, PloS one.

[22]  W. Fiers,et al.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments , 2009, Expert review of vaccines.

[23]  J. Kwang,et al.  Gastrointestinal Delivery of Baculovirus Displaying Influenza Virus Hemagglutinin Protects Mice against Heterologous H5N1 Infection , 2010, Journal of Virology.

[24]  R. Couch,et al.  Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. , 2006, The Journal of infectious diseases.

[25]  R. Couch,et al.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. , 2007, Vaccine.

[26]  D. Tang,et al.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines , 2009, Expert review of vaccines.

[27]  G. Kemble,et al.  Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs , 2009, Journal of Virology.

[28]  J. Katz,et al.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice , 2006, The Lancet.

[29]  L. Sticchi,et al.  Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. , 2010, Vaccine.

[30]  Erin Burns,et al.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. , 2010, MMWR. Morbidity and mortality weekly report.

[31]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Elmets,et al.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.

[33]  R. Couch,et al.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. , 2009, Vaccine.

[34]  R. Bugarini,et al.  Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers , 2006, Journal of Virology.

[35]  T. Popow-Kraupp,et al.  A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. , 2010, The Journal of infectious diseases.

[36]  J. Haensler,et al.  Emulsion-based adjuvants for influenza vaccines , 2009, Expert review of vaccines.

[37]  J. Oxford,et al.  Evidence for host-cell selection of influenza virus antigenic variants , 1983, Nature.

[38]  F. Hayden,et al.  Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. , 2007, JAMA.

[39]  P. P. Laidlaw,et al.  A Virus obtained from influenza patients , 1933 .

[40]  R. Couch,et al.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[42]  R. Webster,et al.  Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus , 1990, Journal of virology.

[43]  K. Johansen,et al.  Pandemic influenza A(H1N1) 2009 vaccines in the European Union. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  Mark R. Soboleski,et al.  Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. , 2009, Vaccine.

[45]  B. Murphy,et al.  Development of effective vaccines against pandemic influenza. , 2006, Immunity.

[46]  J. Taubenberger,et al.  1918 Influenza: the Mother of All Pandemics , 2006, Emerging infectious diseases.

[47]  T. Cherian,et al.  A review of vaccine research and development: Human acute respiratory infections , 2005, Vaccine.

[48]  D. Persing,et al.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.

[49]  R. Rappuoli,et al.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. , 2008, Vaccine.

[50]  J. Haynes,et al.  Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.

[51]  Jin Hyang Kim,et al.  DNA vaccines against influenza viruses. , 2009, Current topics in microbiology and immunology.

[52]  N. Sardesai,et al.  Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens , 2008, PloS one.

[53]  K. Nichol,et al.  Vaccines for seasonal and pandemic influenza. , 2006, The Journal of infectious diseases.

[54]  G. Kobinger,et al.  Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-Term Sterilizing Immunity against Heterologous Challenge , 2010, Journal of Virology.

[55]  Shibo Jiang,et al.  Research and development of universal influenza vaccines. , 2010, Microbes and infection.

[56]  G. Schild,et al.  Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. , 1971, The Journal of infectious diseases.